Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Entrepreneurship Guest Lecture Series

Publication date: Dec 06, 2012 02:11 PM

Start: Dec 06, 2012 05:15 PM

[image reference is broken]

Jon Bradford - CEO and Co-founder, Springboard
Springboard combines investment capital with an intensive 13 week mentor-led accelerator programme.

Whilst the Springboard program is based at Google Campus in London and ideaSpace in Cambridge, it is aimed at ambitious and scalable early stage businesses from both UK and overseas.